医药财报速递｜再生元制药二季度：核心产品双强，管线信号分化

from 投研随身听 · host 慢研播客

再生元制药本季偏强，原有判断强化。杜匹克森特和艾力雅高剂量版共同驱动增长，成本指引改善；但公认会计准则利润下降、传统艾力雅受侵蚀，黑色素瘤项目未达主要终点。

Episode metadata supplied by the publisher feed · Published Aug 4, 2026

Embed this episode

Attribution link and audio player

Ready to play

医药财报速递｜再生元制药二季度：核心产品双强，管线信号分化

0:00 5:20

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

This episode is 5 minutes long.

This episode was published on August 4, 2026.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!